Use of carbamate compound for preventing or treating trigeminal neuralgia

Use of a carbamate compound of the following Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, for the prevention or treatment of trigeminal neuralgia:

• wherein,
• R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, halo-C1-C8 alkyl, C1-C8 thioalkoxy and C1-C8 alkoxy;
• and
• one of A1 and A2 is CH, and the other is N.

A method for treating trigeminal neuralgia in a subject, comprising:

• administering to the subject a pharmaceutical composition comprising a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a pharmaceutically acceptable carrier:
• wherein,
• R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, halo-C1-C8 alkyl, C1-C8 thioalkoxy and C1-C8 alkoxy;
• and
• one of A1 and A2 is CH, and the other is N,
• wherein the step of administering is oral administration, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, intravaginal administration, intrapulmonary administration, or rectal administration.